Yatai Pharmaceutical to Establish Subsidiary for Pioneering Photodynamic Drug and Device Development

Stock News
06/11

Zhejiang Yatai Pharmaceutical Co.,Ltd. (SHE: 002370) has announced plans to establish a new subsidiary, a strategic move aimed at expanding its industrial footprint.

The company's wholly-owned subsidiary, Yatai Lizhong, intends to use its own funds of 20 million yuan to set up Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (tentative name).

This initiative is part of the company's strategic and operational planning, designed to further refine its industrial development layout.

Photodynamic therapy (PDT) is a medical technique that utilizes photosensitizers, specific wavelengths of light, and oxygen molecules to destroy diseased tissue. It is widely used in cancer treatment, dermatology, and certain inflammatory diseases, representing a cutting-edge field in the healthcare industry.

The core principle involves activating photosensitizers within the lesion using light, generating reactive oxygen species to kill target cells. This method offers advantages such as precise targeting, minimal invasiveness, and rapid recovery.

In recent years, advancements in photosensitizing substances, light sources, and light delivery systems have propelled PDT forward. Its low toxicity, protective effects on organ function, and unique clinical advantages in treating superficial proliferative lesions on body surfaces and in cavities have established it as a significant treatment for tumors and various benign conditions.

The investment is driven by the company's strategic planning and future development needs. It represents an active move to enter the new field of photodynamic therapy.

By leveraging its existing business foundation and resource advantages, the company aims to integrate industrial resources related to photodynamics. The focus will be on strengthening the research, development, and industrialization of photodynamic drugs.

A key objective is to explore the development of innovative photodynamic drugs and their supporting medical devices.

This effort is expected to cultivate new business growth points for the company, optimize its business structure, enhance overall profitability and core competitiveness, and promote long-term sustainable development.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10